Working... Menu
Trial record 7 of 7 for:    12181401 [PUBMED-IDS]

Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00290485
Recruitment Status : Unknown
Verified April 2006 by Maisonneuve-Rosemont Hospital.
Recruitment status was:  Recruiting
First Posted : February 13, 2006
Last Update Posted : April 7, 2006
Hippocrate Research & Development
Information provided by:
Maisonneuve-Rosemont Hospital

Brief Summary:
The aim of this study is to demonstrate that the use of Gleevec in initially non-resectable gastrointestinal stromal tumors can lead to allow complete resection in 20% of cases.

Condition or disease Intervention/treatment Phase
Gastrointestinal Stromal Tumors Drug: Imatinib mesylate Phase 2

Detailed Description:
Gastrointestinal stromal tumor (GIST) is a specific, immunohistochemically KIT+ mesenchymal neoplasm of the gastrointestinal tract. The identification of KIT+ tumor has become more important after introduction of target treatment with KIT tyrosine kinase inhibitor Imatinib mesylate (Gleevec). Despite this progress, GIST patients presenting a tumor larger than 5 cm have a 10 year survival between 10% and 30%. Indeed, the risk of microscopic spreading of the tumor during surgery is very high since intra-abdominal organs are in close relation to each others. To improve survival, it seemed logical to use preoperative Gleevec to reduce tumor size and improve efficacy of the surgical procedure.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 50 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study on Preoperative Administration of Gleevec in Patients With Initially Non-Resectable Gastrointestinal Stromal Tumor
Study Start Date : August 2005

Primary Outcome Measures :
  1. Patient response rate according to RECIST criteria

Secondary Outcome Measures :
  1. Clinical response to treatment
  2. Radiological response to treatment
  3. Pathological response to treatment
  4. Compare clinical with pathological response
  5. Evaluate the impact of Gleevec on surgical morbidity
  6. Evaluate disease-free survival
  7. Evaluate overall survival
  8. Evaluate whether the response rate can predict survival

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • GIST patient considered initially non-resectable as defined by one of the following:

    1. when the surgical team considers that the risk of incomplete resection (R1 or R2) of a GIST is higher than 20%
    2. when the resection of a GIST necessitates a highly morbid procedure
    3. when a GIST is attached to 3 or more major intra-abdominal structures or to a major intra-abdominal blood vessel
    4. when GIST is considered at very high risk of recurrence. This is the case when it is a recurrence or when the tumor is in very close contact with a structure that cannot be resected by surgery or when the patient has metastasis.
  • Outpatient is 18 years old or more
  • ECOG performance status 0, 1 or 2
  • Immunohistochemical confirmation of KIT overexpression must exist at the study entry
  • Measurable disease on CT-Scan or MRI (ultrasound and/or operative finding are not acceptable) and response to RECIST criteria
  • Have a life expectancy of at least 6 months
  • Be willing and able to comply with the protocol (and surgery if required) for the duration of the study
  • Give written informed consent prior to study-specific screening procedure, with the understanding that the patient has the right to withdraw from the study at any time without prejudice

Exclusion Criteria:

  • received Imatinib in the past
  • received a full course of radiotherapy within 3 months of inclusion in the study. A short course of radiotherapy to control bleeding is allowed.
  • received systemic chemotherapy within 4 weeks of inclusion in the study
  • received steroids for less than 4 weeks of inclusion in the study
  • pregnant or lactating women
  • women of childbearing potential with either a positive or no pregnancy test at baseline. Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential.
  • sexually active males or females (of childbearing potential) unwilling to practice contraception during the study
  • history of other malignancy within the past 5 years, except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix
  • clinical or other evidence of CNS metastases
  • myocardial infarction within the last 3 months
  • any medical condition that contraindicates potential surgery
  • lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome or inability to take oral medication
  • any serious uncontrolled concomitant disease
  • any of the following laboratory values:

    1. absolute neutrophil count < 1.5 E+09/L
    2. platelet count < 80000 E+09/L
    3. AST or ALT higher than 2 X normal
  • major surgery within 4 weeks prior to start of study treatment, or lack of complete recovery from effects of major surgery
  • patients with known or suspected hypersensitivity to one of the Gleevec components.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00290485

Layout table for location contacts
Contact: Pierre Dubé, MD (514) 252-3822

Layout table for location information
Canada, Quebec
Maisonneuve-Rosemont Hospital Recruiting
Montreal, Quebec, Canada, h1t 2m4
Contact: Pierre Dubé, MD    (514) 252-3822   
Principal Investigator: Pierre Dubé, MD         
Sponsors and Collaborators
Maisonneuve-Rosemont Hospital
Hippocrate Research & Development
Layout table for investigator information
Study Chair: Pierre Dubé, MD Maisonneuve-Rosemont Hospital


Layout table for additonal information Identifier: NCT00290485     History of Changes
Obsolete Identifiers: NCT00363103
Other Study ID Numbers: Q-CTG-01-V7.0-A1
First Posted: February 13, 2006    Key Record Dates
Last Update Posted: April 7, 2006
Last Verified: April 2006

Keywords provided by Maisonneuve-Rosemont Hospital:
non-resectable tumor
high-risk tumor
Response Evaluation Criteria in Solid Tumors (RECIST)
Imatinib mesylate

Additional relevant MeSH terms:
Layout table for MeSH terms
Gastrointestinal Stromal Tumors
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Gastrointestinal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Imatinib Mesylate
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action